dc.contributor.author |
Kendall, Jackie |
en |
dc.contributor.author |
Rewcastle, Gordon |
en |
dc.contributor.author |
Frédérick, Raphaël |
en |
dc.contributor.author |
Mawson, Claire |
en |
dc.contributor.author |
Denny, William |
en |
dc.contributor.author |
Marshall, Elaine |
en |
dc.contributor.author |
Baguley, Bruce |
en |
dc.contributor.author |
Chaussade, Claire |
en |
dc.contributor.author |
Jackson, SP |
en |
dc.contributor.author |
Shepherd, Peter |
en |
dc.date.accessioned |
2011-11-18T02:16:59Z |
en |
dc.date.issued |
2007 |
en |
dc.identifier.citation |
Bioorganic & Medicinal Chemistry 15(24):7677-7687 2007 |
en |
dc.identifier.issn |
0968-0896 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/9386 |
en |
dc.description.abstract |
A series of 2-methyl-5-nitrobenzenesulfono-hydrazides were prepared and evaluated as inhibitors of PI3K. An isoquinoline derivative shows good selectivity for the p110a isoform over p110b and p110d, and also demonstrates good in vitro activity in a cell proliferation assay. Molecular modelling provides a rationalisation for the observed SAR. |
en |
dc.language |
EN |
en |
dc.publisher |
Elsevier Ltd. |
en |
dc.relation.ispartofseries |
Bioorganic & Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from
http://www.sherpa.ac.uk/romeo/issn/0968-0896/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
PI3K |
en |
dc.subject |
p110 alpha |
en |
dc.subject |
sulfonohydrazide |
en |
dc.subject |
PHOSPHATIDYLINOSITOL 3-KINASE |
en |
dc.subject |
P110-ALPHA INHIBITORS |
en |
dc.subject |
CANCER |
en |
dc.subject |
WORTMANNIN |
en |
dc.subject |
MUTATIONS |
en |
dc.subject |
MECHANISM |
en |
dc.subject |
ALCOHOLS |
en |
dc.title |
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110 alpha inhibitors |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.bmc.2007.08.062 |
en |
pubs.issue |
24 |
en |
pubs.begin-page |
7677 |
en |
pubs.volume |
15 |
en |
dc.rights.holder |
Copyright: Elsevier Ltd. |
en |
dc.identifier.pmid |
17869522 |
en |
pubs.end-page |
7687 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
72608 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Molecular Medicine |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
17869522 |
en |